ASLN ASLAN Pharmaceuticals Limited

+0.21  (+7%)
Previous Close 3.23
Open 3.38
Price To Book 3.58
Market Cap 110,251,271
Shares 32,049,788
Volume 1,624
Short Ratio
Av. Daily Volume 16,901

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 data due 2H 2019.
Varlitinib - TREETOPP
Biliary tract cancer
Phase 2 trial did not meet primary endpoint - January 13, 2019.
Gastric cancer
Phase 2 Part 1 data due 2Q 2019. Timeline missed. Estimate 3Q 2019.
Acute Myeloid Leukemia (AML)
Phase 1/2 new data presented at at ASCO Gastrointestinal Cancers Symposium January 2019.
Varlitinib + gemcitabine and cisplatin
Biliary tract cancer
Phase 1 completion announced June 4, 2019. MAD trial to be initiated 2H 2019.
Atopic dermatitis

Latest News

  1. ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why
  2. ASLAN Pharmaceuticals Completes Phase 1 Study for ASLAN004 Targeting Atopic Dermatitis
  3. ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL
  4. ASLAN Pharmaceuticals’ Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric Cancer
  5. ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's Why
  6. ASLAN Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
  7. Top Ranked Momentum Stocks to Buy for March 29th
  8. ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis
  9. ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  10. ASLAN Pharmaceuticals Signs New Agreement With Biogenetics for Commercialisation of ASLAN003 in South Korea
  11. ASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South Korea
  12. ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring
  13. ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines
  14. ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI
  15. ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
  16. ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer
  17. ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period
  18. ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule
  19. New Data on ASLAN003 Presented at Ash Annual Meeting Shows First Signs of Clinical Activity of a DHODH Inhibitor in Acute Myeloid Leukaemia